Avalo Therapeutics (NASDAQ:AVTX) Stock Rating Lowered by Zacks Investment Research

Zacks Investment Research cut shares of Avalo Therapeutics (NASDAQ:AVTX) from a buy rating to a sell rating in a research note released on Tuesday morning, Zacks.com reports.

According to Zacks, “Avalo Therapeutics Inc. is a clinical-stage precision medicine company which discovers, develops and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology and rare genetic diseases. Avalo Therapeutics Inc., formerly known as Cerecor, is based in WAYNE, Pa. “

A number of other brokerages also recently weighed in on AVTX. Royal Bank of Canada started coverage on Avalo Therapeutics in a report on Friday, September 24th. They issued an outperform rating and a $6.00 target price on the stock. Oppenheimer reaffirmed a buy rating and issued a $5.00 target price on shares of Avalo Therapeutics in a report on Friday, January 7th.

Shares of Avalo Therapeutics stock opened at $1.00 on Tuesday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 4.04 and a current ratio of 4.04. The firm has a 50-day moving average price of $1.86. Avalo Therapeutics has a one year low of $0.90 and a one year high of $4.50.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings data on Tuesday, November 9th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.01. The firm had revenue of $1.35 million for the quarter. Avalo Therapeutics had a negative return on equity of 272.08% and a negative net margin of 1,211.01%. Analysts predict that Avalo Therapeutics will post -0.84 earnings per share for the current fiscal year.

In other news, Director Armistice Capital, Llc purchased 137,900 shares of the company’s stock in a transaction dated Friday, January 7th. The stock was bought at an average cost of $1.04 per share, for a total transaction of $143,416.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders bought a total of 780,854 shares of company stock valued at $783,249 over the last quarter. 45.70% of the stock is owned by corporate insiders.

A number of large investors have recently made changes to their positions in AVTX. Caas Capital Management LP acquired a new stake in Avalo Therapeutics during the 3rd quarter worth about $26,000. Cambridge Investment Research Advisors Inc. acquired a new stake in Avalo Therapeutics during the 3rd quarter worth about $27,000. Creative Planning acquired a new stake in Avalo Therapeutics during the 3rd quarter worth about $32,000. Victory Capital Management Inc. acquired a new stake in Avalo Therapeutics during the 3rd quarter worth about $34,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Avalo Therapeutics in the 3rd quarter valued at about $41,000. 75.60% of the stock is owned by institutional investors and hedge funds.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation.

Featured Article: Stock Symbols and CUSIP Explained

Get a free copy of the Zacks research report on Avalo Therapeutics (AVTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.